Advanced Accelerator Applications Announces Presentations

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advanced Accelerator Applications Announces Presentations on Lutathera® NETTER-1 Phase III and NeoBOMB1 at EANM

SAINT-GENIS-POUILLY, France, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ: AAAP ) (“AAA” or the “Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that data from the pivotal NETTER-1 Phase III study investigating the treatment of Lutathera ® (lutetium Lu 177 dotatate) in patients with somatostatin receptor positive midgut neuroendocrine tumors (midgut NETs) and preclinical oncology studies with NeoBOMB1, a novel GRPR antagonist, will be presented at the 29 th Annual Congress of the European Association of Nuclear Medicine (EANM), October 15-19, in Barcelona, Spain.

The details of the presentations are as follows:

Presentation #OP394: NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177 Lu-Dotatate: Efficacy and Safety Results   Session: 1004 - Do.MoRe: Neuroendocrine Tumours Session Date: October 17, 2016 Session Time: 17:14 – 17:25 Central European Time

Presentation #OP150: Theranostic perspectives of [ 67 Ga/ 111 In/ 177 Lu] NeoBOMB1 in prostate cancer - First evidence for clinical translation with [ 68 Ga] NeoBOMB1 and PET/CT Session: 410 - Late Breaking Abstracts: "The Presidential Session" Session Date: October 16, 2016 Session Time: 15:03 – 15:47 Central European Time

Presentation #OP340: [ 68 Ga] NeoBOMB1, a new candidate in the diagnosis of breast cancer: First results in GRPR-expressing cells and animal models Session: 905 - M2M: Radiolabelled Peptides Session Date: October 17, 2016 Session Time: 14:30 – 14:41 Central European Time

Presentation #OP547: NeoBOMB1, a novel GRP analog, for theranostic use in oncology Session: 1405 - M2M/Do.MoRe - Featured: Radionuclide Therapy - Preclinical Session Date: October 18, 2016 Session Time: 15:29 – 15:40 Central European Time

About Lutathera ®

Lutathera ® (or lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue peptide currently in development for the treatment of gastro entero pancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera ® belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting carcinoid tumors with radiolabeled somatostatin analogue peptides. This novel compound has received orphan drug designation from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Lutathera ® was also granted fast-track designation by the FDA in April 2015 for the treatment of inoperable, progressive midgut NETs. Currently, Lutathera ® is also administered on a compassionate use and named patient basis for the treatment of NETs and other tumors over-expressing somatostatin receptors in ten European countries and in the US under an Expanded Access Program (EAP) for midgut NETs. In an analysis of the NETTER-1 Phase III trial’s primary endpoint of PFS assessment completed in September 2015, the number of disease progressions or deaths was 23 in the Lutathera ® arm and 68 in the Octreotide LAR 60 mg arm. The NETTER-1 study met its primary endpoint by demonstrating that treatment with Lutathera ® was associated with a statistically significant and clinically meaningful risk reduction of 79% of disease progression or death versus Octreotide LAR 60 mg (hazard ratio 0.21, 95% CI: 0.13-0.33; p<0.0001). NDA and MAA submissions to the FDA and EMA are currently under review and the FDA has granted Priority Review.

About NeoBOMB1

NeoBOMB1 is a new generation antagonist bombesin analogue, which binds selectively and with high affinity to the GRP receptors expressed by several types of tumors, including prostate, breast and gastro-intestinal stromal tumors. GRP receptors are considered excellent molecular targets for both therapeutic and diagnostic purposes in those cancers. In vitro and in vivo pre-clinical models have shown that NeoBOMB1 has suitable imaging properties as well as a favorable pharmacokinetic and safety profile. AAA is currently planning three clinical studies with NeoBOMB1 in different indications including gastrointestinal stromal tumors, prostate cancer and breast cancer.

About Advanced Accelerator Applications

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA’s lead therapeutic product candidate, Lutathera ® , is a novel MNM compound that AAA is currently developing for the treatment of neuroendocrine tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 22 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 450 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). AAA reported sales of €88.6 million in 2015 (+26.8% vs. 2014) and sales of €54.6 million for 1H 2016 (+26.9% vs. 1H15). AAA is listed on the Nasdaq Global Select Market under the ticker “AAAP”. For more information, please visit: www.adacap.com .

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera ® and other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance of our products or product candidates; the rate and degree of market acceptance and the clinical utility of Lutathera ® and our other products or product candidates; our estimates regarding the market opportunity for Lutathera ® , our other product candidates and our existing products; our anticipation that we will generate higher sales as we diversify our products; our ability to implement our growth strategy including expansion in the U.S.; our ability to sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position; legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access or distribution channels; and general economic, political, demographic and business conditions in Europe, the U.S. and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts: AAA Corporate Communications Rachel Levine Director of Communications rachel.levine@adacap.com Tel: + 1-212-235-2395 AAA Investor Relations Jordan Silverstein Director of Investor Relations jordan.silverstein@adacap.com Tel: + 1-212-235-2394 Media inquiries: Axess Public Relations (Italy) Dario Francolino dario.francolino@axesspr.com Tel: +39 3488818029

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 50

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 60

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading

Top 5 Most Recently Viewed Articles

Darja Bolshakova Takes the Helm as CFO at Arco Vara Group

Updated Category News Views 239

Darja Bolshakova Appointed as New CFO of Arco Vara The Management Board of Arco Vara AS is excited to announce the appointment of Darja Bolshakova as the Chief Financial Officer. This strategic move is aimed at enhancing the leadership team as the company continues to grow and navigate through evolving market conditions. Years of Expertise in Finance Darja Bolshakova...

Continue Reading
TruGolf Partners with Golf Everywhere for Innovative Facility

Updated Category News Views 175

TruGolf Selected as Exclusive Supplier for Golf Everywhere TruGolf Holdings, Inc. (NASDAQ: TRUG) is thrilled to announce its role as the exclusive golf simulator supplier for the upcoming Golf Everywhere facility, which is set to break ground later this year. This facility, measuring approximately six acres, will become the largest indoor golf venue in the United States,...

Continue Reading
Navigator Unveils Innovative Platform for Local Government Funding

Updated Category News Views 248

Navigator Launches to Revolutionize Local Government Funding Navigator is on a mission to connect communities across the nation with billions of dollars in funding opportunities. By introducing two groundbreaking solutions—Funding Navigator and Pipeline Navigator—this innovative platform helps organizations of all sizes simplify their grant applications and break...

Continue Reading
CData Unveils Integration Accelerator to Streamline Data Workflows

Updated Category News Views 253

CData Unveils Innovative Integration Accelerator for Databricks Purpose-built solution reduces data pipeline complexity and accelerates integration across hybrid and multi-cloud Databricks environments. CData, a prominent player in the data connectivity and integration landscape, has announced an exciting advancement with the launch of its Integration Accelerator designed...

Continue Reading
Goldman Sachs Boosts Weyerhaeuser’s Potential with Buy Rating

Updated Category News Views 75

Goldman Sachs Affirms Weyerhaeuser's Growth Potential Goldman Sachs has recently confirmed its optimistic view of Weyerhaeuser (NYSE: WY) by maintaining a Buy rating and setting a price target of $38.00. This announcement follows insightful discussions with the company's leadership, including Chief Financial Officer Davie Wold and Vice President of Investor Relations Andy...

Continue Reading